CN102618420A - 一种养生保健酒以及制作方法 - Google Patents
一种养生保健酒以及制作方法 Download PDFInfo
- Publication number
- CN102618420A CN102618420A CN2011100301734A CN201110030173A CN102618420A CN 102618420 A CN102618420 A CN 102618420A CN 2011100301734 A CN2011100301734 A CN 2011100301734A CN 201110030173 A CN201110030173 A CN 201110030173A CN 102618420 A CN102618420 A CN 102618420A
- Authority
- CN
- China
- Prior art keywords
- grams
- health
- fructus amomi
- effect
- chrysanthemum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 34
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims abstract description 29
- 244000223014 Syzygium aromaticum Species 0.000 claims abstract description 28
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 15
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 14
- 241000804384 Cynomorium songaricum Species 0.000 claims abstract description 12
- 244000062241 Kaempferia galanga Species 0.000 claims abstract description 12
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 11
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 11
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 11
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 11
- OEYQBKYISMRWQB-UHFFFAOYSA-N Santal Chemical compound C=1C(OC)=CC(O)=C(C2=O)C=1OC=C2C1=CC=C(O)C(O)=C1 OEYQBKYISMRWQB-UHFFFAOYSA-N 0.000 claims description 24
- 235000013422 Kaempferia rotunda Nutrition 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- 244000062250 Kaempferia rotunda Species 0.000 claims description 15
- 210000000582 semen Anatomy 0.000 claims description 15
- 244000246386 Mentha pulegium Species 0.000 claims description 12
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 12
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 12
- 235000001050 hortel pimenta Nutrition 0.000 claims description 12
- 241000212321 Levisticum Species 0.000 claims description 11
- 235000019082 Osmanthus Nutrition 0.000 claims description 11
- 241000333181 Osmanthus Species 0.000 claims description 11
- 230000012010 growth Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 7
- 238000007789 sealing Methods 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 4
- 241000395033 Kaempferia Species 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 41
- 210000002784 stomach Anatomy 0.000 abstract description 17
- 230000028327 secretion Effects 0.000 abstract description 10
- 230000006870 function Effects 0.000 abstract description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 5
- 206010022437 insomnia Diseases 0.000 abstract description 5
- 210000000936 intestine Anatomy 0.000 abstract description 5
- 210000003734 kidney Anatomy 0.000 abstract description 4
- 210000001835 viscera Anatomy 0.000 abstract description 3
- 240000000513 Santalum album Species 0.000 abstract description 2
- 235000008632 Santalum album Nutrition 0.000 abstract description 2
- 238000013461 design Methods 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241001254604 Angelica pubescens Species 0.000 abstract 1
- 241000252804 Cinnamomum insularimontanum Species 0.000 abstract 1
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 235000013421 Kaempferia galanga Nutrition 0.000 abstract 1
- 235000006679 Mentha X verticillata Nutrition 0.000 abstract 1
- 235000002899 Mentha suaveolens Nutrition 0.000 abstract 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 abstract 1
- 244000088415 Raphanus sativus Species 0.000 abstract 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 abstract 1
- 230000003796 beauty Effects 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 15
- 230000000452 restraining effect Effects 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- 230000000845 anti-microbial effect Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000522254 Cassia Species 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 241000628997 Flos Species 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 240000005250 Chrysanthemum indicum Species 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- 241000223238 Trichophyton Species 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001480043 Arthrodermataceae Species 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241000193738 Bacillus anthracis Species 0.000 description 3
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 3
- 239000005770 Eugenol Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 241000130764 Tinea Species 0.000 description 3
- 208000002474 Tinea Diseases 0.000 description 3
- 241000607626 Vibrio cholerae Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000037304 dermatophytes Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 206010013023 diphtheria Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229960002217 eugenol Drugs 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 201000005917 gastric ulcer Diseases 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 229940118696 vibrio cholerae Drugs 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 2
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 2
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 2
- 241000227129 Aconitum Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241001480035 Epidermophyton Species 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 206010042220 Stress ulcer Diseases 0.000 description 2
- QKGJFQMGPDVOQE-UHFFFAOYSA-N Sulforaphen Natural products CS(=O)C=CCCN=C=S QKGJFQMGPDVOQE-UHFFFAOYSA-N 0.000 description 2
- 206010043994 Tonic convulsion Diseases 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000001716 anti-fugal effect Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 2
- 229940117916 cinnamic aldehyde Drugs 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008821 health effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229960001252 methamphetamine Drugs 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- QKGJFQMGPDVOQE-HWKANZROSA-N raphanin Chemical group CS(=O)\C=C\CCN=C=S QKGJFQMGPDVOQE-HWKANZROSA-N 0.000 description 2
- 239000003507 refrigerant Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 206010061393 typhus Diseases 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- NQBWNECTZUOWID-UHFFFAOYSA-N (E)-cinnamyl (E)-cinnamate Natural products C=1C=CC=CC=1C=CC(=O)OCC=CC1=CC=CC=C1 NQBWNECTZUOWID-UHFFFAOYSA-N 0.000 description 1
- LAOOXBLMIJHMFO-UHFFFAOYSA-N 1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one;hydron;chloride Chemical compound Cl.S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC LAOOXBLMIJHMFO-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- GGRLKHMFMUXIOG-UHFFFAOYSA-M 2-acetyloxyethyl(trimethyl)azanium;hydroxide Chemical compound [OH-].CC(=O)OCC[N+](C)(C)C GGRLKHMFMUXIOG-UHFFFAOYSA-M 0.000 description 1
- CFRFHWQYWJMEJN-UHFFFAOYSA-N 9h-fluoren-2-amine Chemical compound C1=CC=C2C3=CC=C(N)C=C3CC2=C1 CFRFHWQYWJMEJN-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000499399 Cynomoriaceae Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001263448 Mycetozoa Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 241000245665 Taraxacum Species 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241001480046 Trichophyton schoenleinii Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000003005 anti-senility effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- NQBWNECTZUOWID-QSYVVUFSSA-N cinnamyl cinnamate Chemical compound C=1C=CC=CC=1\C=C/C(=O)OC\C=C\C1=CC=CC=C1 NQBWNECTZUOWID-QSYVVUFSSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- -1 convergence Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- WTYGAUXICFETTC-UHFFFAOYSA-N cyclobarbital Chemical compound C=1CCCCC=1C1(CC)C(=O)NC(=O)NC1=O WTYGAUXICFETTC-UHFFFAOYSA-N 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 150000008195 galaktosides Chemical class 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 229940069016 go-dry Drugs 0.000 description 1
- 231100000652 hormesis Toxicity 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001053 orthosympathetic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229910052957 realgar Inorganic materials 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 230000001843 schistosomicidal effect Effects 0.000 description 1
- 230000007226 seed germination Effects 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- OJYLAHXKWMRDGS-UHFFFAOYSA-N zingerone Chemical compound COC1=CC(CCC(C)=O)=CC=C1O OJYLAHXKWMRDGS-UHFFFAOYSA-N 0.000 description 1
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 description 1
- 229930001895 zingiberene Natural products 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及电气设计领域,公开了一种养生保健酒以及制作方法。保健酒由以下组成:水:5千克,原酒:20斤1千克,当归:6克,陈皮:15克,红豆蔻:3克,白豆蔻:3克,官桂:3克,山奈:3克,高良姜:3克,独活:3克,锁阳:3克,薄荷:3克,莱菔子:3克,砂仁:3克,甘草:3克,檀香:3克,丁香:3克,栀子:30克,山药:3克,菊花:3克。其可以调整五胀对风湿类风湿、肠胃、高血脂、肾功能、对失眠、内分泌及美容养颜效极佳。
Description
技术领域
本发明涉及电气设计领域,尤其涉及一种养生保健酒以及制作方法。
背景技术
酒是中国古老的中国文化之一。保健酒已有数千年的历史,是中国医药科学的重要组成部分。
发明内容
本发明实施例第一目的在于提供:一种养生药酒,其可以调整五胀对风湿类风湿、肠胃、高血脂、肾功能、对失眠、内分泌及美容养颜极佳。
本发明实施例第二目的在于提供:一种养生药酒的制备方法,其制的保健酒可以调整五胀对风湿类风湿、肠胃、高血脂、肾功能、对失眠、内分泌及美容养颜极佳。
本发明实施例提供的一种养生保健酒,由以下组成:
水:5千克,原酒:20斤1千克,当归:6克,陈皮:15克,红豆蔻:3克,白豆蔻:3克,官桂:3克,山奈:3克,高良姜:3克,独活:3克,锁阳:3克,薄荷:3克,莱菔子:3克,砂仁:3克,甘草:3克,檀香:3克,丁香:3克,栀子:30克,山药:3克,菊花:3克。
可选地,所述当归、陈皮、红豆蔻、白豆蔻、官桂、山奈、高良姜、独活、锁阳、薄荷、莱菔子、砂仁、甘草、檀香、丁香、栀子、山药、菊花选用河南省焦作市内生长的药物。
本实施例得到的一种养生保健酒的制作方法,包括:
将栀子30克放入5千克水中煮沸;
在处于沸腾状态下的栀子水中混入1千克的原酒、以及以下药材:当归:6克,陈皮:15克,红豆蔻:3克,白豆蔻:3克,官桂:3克,山奈:3克,高良姜:3克,独活:3克,锁阳:3克,薄荷:3克,莱菔子:3克,砂仁:3克,甘草:3克,檀香:3克,丁香:3克,山药:3克,菊花:3克;
封口密封浸泡3天。
可选地,所述当归、陈皮、红豆蔻、白豆蔻、官桂、山奈、高良姜、独 活、锁阳、薄荷、莱菔子、砂仁、甘草、檀香、丁香、栀子、山药、菊花选用河南省焦作市内生长的药物。
由上可见,应用本发明实施例的技术方案,本实施例的养生药酒,具有气味香浓,而且经实践表明,对调整五脏高血脂、肾功能、对失眠、内分泌及美容养颜具有良好的调理作用,并且毒性小,适合长期饮用。且纯天然不加任何色素。
附图说明
此处所说明的附图用来提供对本发明的进一步理解,构成本申请的一部分,并不构成对本发明的不当限定,在附图中:
图1为本发明实施例1提供的一种养生药酒制作方法流程示意图。
具体实施方式
下面将结合附图以及具体实施例来详细说明本发明,在此本发明的示意性实施例以及说明用来解释本发明,但并不作为对本发明的限定。
实施例1:
本实施例提供的一种养生保健酒,其由以下组成:水:5千克,原酒:20斤1千克,当归:6克,陈皮:15克,红豆蔻:3克,白豆蔻:3克,官桂:3克,山奈:3克,高良姜:3克,独活:3克,锁阳:3克,薄荷:3克,莱菔子:3克,砂仁:3克,甘草:3克,檀香:3克,丁香:3克,栀子:30克,山药3克,菊花3克。
其中,当归具有补血活血,调经止痛,润肠通便的的药理作用。对于血虚萎黄、眩晕心悸、***、经闭痛经、虚寒腹痛、肠燥便秘、风湿痹痛、跌扑损伤、痈疽疮疡有较为明显的作用。
陈皮,性温、味辛、苦。而温能行气,辛能发散,苦而泄水,故陈皮具有以下的三大药理作用:一是导胸中寒邪,二破滞气,三益脾胃。
红豆蔻,是高高良姜的种子,其辛、温、无毒辣。故其具有温中散寒、醒脾解酒的药理功效。
白豆蔻,主要用于湿阻脾胃,脘腹胀满,不思饮食,胸闷气滞,以及湿温初起等症。且白豆蔻气味芳香,辛温通散,功能化湿醒脾,兼能行气对湿 阻气滞作用较好,可与陈皮等同用。且本品气清上浮,能入肺经,又可用于气滞胸闷之症。
官桂是肉桂的一种,对中枢神经***具有以下作用:经本发明人实践发现如下:
镇静作用:肉桂中含有的桂皮醛对小鼠有明显的镇静作用,表现为自发活动减少,对抗甲基***(Methamphetamine)所产生的过多活动、转棒试验产生的运动失调以及延长环己巴比妥钠的麻醉时间等。应用小鼠压尾刺激或腹腔注射醋酸观察扭体运动的方法证明它有镇痛作用。
降温作用:对小鼠正常体温以及用伤寒、副伤寒混合疫苗引起的人工发热均有降温作用。对温刺引起发热的家兔,桂皮醛及肉桂酸钠都有解热作用。可延迟***引起的强直性惊厥及死亡的时间,可减少菸碱引起的强直性惊厥及死亡的发生率。对戌四唑引起者则无效。
降压作用:附子、肉桂复方对肾上腺皮质性高血压大鼠(灼伤一侧肾上腺所形成之模型)有降压作用;对肾性高血压大鼠(8字形结扎肾脏所形成之模型),则无作用。此作用可能是附子、肉桂促进机能降低了的肾上腺活动,使之趋向正常所致。
预防吸血虫病的作用:小鼠每天口服浸剂(未注明品种)0.2ml/10g体重(10.8g/180ml),共服15天,服药之第3天感染血吸虫,并无预防作用,如与雄黄、槟榔及阿魏同用则有一定效果。对血液的作用:肉桂体外及体内试验,均有明显抑制ADP诱导的大鼠血小板聚集的作用,体外试验显示肉桂水煎剂及溶甲醇部分有较强的抗凝作用。从肉桂中提取的单体一肉桂酸及香豆素,抗凝作用不明显。体内试验肉桂水煎剂也无抗凝作用,不影响兔纤维蛋白溶解活性。
对消化***还具有以下作用:
健胃作用:桂皮油刺激嗅觉,能反射地促进胃机能,也能直接对胃粘膜有缓和的刺激作用,使分泌增加,蠕动增强,呈芳香性健胃作用。
肠管兴奋作用:桂皮油给家兔口服,能促进肠运动,使肠管兴奋。对离体家兔肠管亦具有同样作用,为古人暖脾胃,除冷积之说作了很好的解释。
山奈,又称三奈、沙姜,具有解毒杀菌的作用,另外,山奈中的姜辣素 能抗衰老,老年人常吃山奈可除“老年斑”;另外,山奈的提取物能刺激胃粘膜,引起血管运动中枢及交感神经的反射性兴奋,促进血液循环,振奋胃功能,达到健胃、止痛、发汗、解热的作用;山奈的挥发油能增强胃液的分泌和肠壁的蠕动,从而帮助消化;山奈中分离出来的姜烯、姜酮的混合物有明显的止呕吐作用;山奈提取液具有显著抑制皮肤真菌和杀灭***滴虫的功效,可治疗各种痈肿疮毒;山奈还有抑制癌细胞活性、降低癌变的毒害作用。
高良姜,本发明人经过实践发现,高良姜煎液(100%)对炭疽杆菌、α-或β-溶血性链球菌、白喉及类白喉杆菌、肺炎球菌、葡萄球菌(金黄色、柠檬色、白色)、枯草杆菌等皆有不同程度的抗菌作用。
独活,本发明人经过实践发现,具有镇痛、镇静、催眠、降压、抑制心肌收缩、抗炎的功效。
锁阳,誉称沙漠“不老药”,主产于青海西部,自生自灭于沙漠之中,列锁阳科,味和性温,肉质寄生草本,茎圆柱状,肉质滋润,富含水溶性B型、还原糖、鞣质等,经实践发现,对于腰膝痿软,阳痿滑精,肠燥便秘有显著疗效。
薄荷,是一种唇形植物,中医用薄荷作为发汗解热剂具有清心怡神,疏风散热,增进食欲,帮助消化的药理效果,且问到清新。
莱菔子,又称萝卜子,经发明人实践发现其具有以下的药理作用:
①抗菌作用莱菔子含抗菌物质,其有效成分为莱菔素,在1毫克/毫升浓度对葡萄球菌秘大肠杆菌即有显著抑制作用,且可影响各种植物种子发芽。从莱菔子中分离出一种油,称为Sulforaphen,1%浓度可对抗链球菌、化脓球菌、肺炎球菌、大肠杆菌等生长。
②抗真菌作用莱菔子水浸剂(1∶3)在试管内对同心性毛癣菌等六种皮肤真菌有不同程度的抑制作用。
③其他作用变种的提取物,长期饲喂大鼠,能干扰甲状腺素的合成
砂仁,可显著减少大鼠的胃酸分泌,对小鼠应激性溃疡有明显的抑制作用。其机制可能是由于促进了胃黏膜细胞释放***素,从而抑制了胃酸分泌。
甘草,主要成分是甘草皂苷,甘草皂苷又称甘草酸,由于有甜味,又称 为甘草甜素。具有抗病毒的药理作用。
檀香,辛香气浓,均有一定的理气作用。其性辛、温;归脾、胃、心、肺经;行心温中,开胃止痛”。能治疗喉咙痛、粉刺、抗感染、抗气,有调理敏感肤质,防止肌肤老化的功效,去邪、去燥、杀菌、防霉、防虫、防蛀,具有安抚神经,辅助冥思、提神静心之功效。
从檀香木中提取的檀香油在医药上也有广泛的用途,具有清凉、收敛、强心、滋补、润滑皮肤等多重功效,可用来治疗胆汁病,膀胱炎、淋病以及腹痛、发热、呕吐等病症,对龟裂、富贵手、黑斑、蚊虫咬伤等症特别有效,古来就是对治皮肤病的重要药品。
丁香,气味香浓,药理作用:
1、抗病原微生物作用在试管内,丁香对葡萄球菌和结核杆菌的生长有抑制作用。丁香水煎剂及粉末对溶血性链球菌有较强的抗菌作用,其抗菌作用且不受加热的影响。实验证明:丁香的醇浸出物对白喉杆菌、炭疽杆菌、副伤寒杆菌、痢疾杆菌、金黄色葡萄球菌、白色葡萄球菌、霍乱弧菌均有抑制作用。丁香油的抗菌能力强於丁香。体外试验证明,丁香的醇浸出物对白喉杆菌、炭疽杆菌、副伤寒杆菌、痢疾杆菌、金黄色葡萄球菌、白色葡萄球菌、霍乱弧菌均有抑制作用。在试管内,丁香油与丁香酚在1∶16000~1∶64000时,可完全阻止布氏杆菌的发育;在1∶8000时则可完全抑制鸟型结核杆菌的发育;在1∶2000~1∶8000浓度时,对金黄色葡萄球菌及肺炎杆菌、痢疾杆菌、大肠杆菌、变形杆菌、结核杆菌均有抑制作用。体外试验证明,丁香对流感病毒PR 8株病毒有抑制作用。
丁香的水、醇及***浸出液和其挥发油,对致病性真菌均有明显的抗真菌作用。低浓度浸出液对许兰黄癣菌、白色念珠菌等有抑制作用。在试管内,丁香油及丁香酚在1∶8000~1∶16000浓度时,对多种毛癣菌、黄癣菌及腹股沟表皮癣菌有抗菌作用。
2、对消化***的作用丁香为芳香健胃剂,可缓解腹部气胀、增强消化能力、减轻恶心呕吐。
研究表明:丁香浸出液有刺激胃酸和胃蛋白酶分泌的作用,其刺激胃液分泌的作用与乙酰胆碱不同,前者刺激分泌的胃液酸度高,消化力较强,而 后者刺激分泌的胃液酸度低,消化力较弱。丁香刺激胃液分泌的作用似与胆碱能神经参与有关,因该作用可被静脉注射阿托品所阻抑。丁香酚乳剂亦可使胃黏液分泌显著增加,而酸度不增强。丁香油的作用稍差。连续应用可使黏液耗竭,而只分泌非黏液性的渗出物。
实验表明:丁香水提取物灌胃,对小鼠水浸应激性溃疡和大鼠盐酸胃溃疡有明显抑制作用;醚提取物灌胃,可明显抑制消炎痛加乙醇诱发的小鼠胃溃疡及盐酸引起的大鼠胃溃疡。
丁香水煎剂灌胃能显著抑制小鼠的胃排空及未尝墨汁推进率;醚提取物灌胃能抑制蓖麻油引起的小鼠腹泻;水提取物灌胃能明显抑制番泻叶引起的小鼠腹泻。但亦有报告认为,水煎剂对两种腹泻模型仅有对抗倾向而无明显影响。
山药,具有健脾、补肺、固肾、益精等多种功效。并且对肺虚咳嗽、脾虚泄泻、肾虚遗精、带下及小便频繁等症,都有一定的疗补作用。
菊花,为常用中药,能疏风清热、平肝明目,其主要成分为挥发油、黄酮类及氨基酸、微量元素等,主要具有以下作用:
1、对冠脉的作用:浙江医科大学研究菊花制剂具有明显增加离体兔心、在体狗心冠脉流量的作用,可使由刺激脑中枢引起的缺血性心电图ST段压低的状况得到改善,提高小白鼠对减压缺氧的耐受性。杨学远等发现杭白菊制剂的酚性部分可以增加豚鼠离体心脏冠脉流量并对家兔的心、肝、肾功能无明显毒性作用。菊花对实验性心肌梗塞、实验性冠脉粥样硬化或供血不足的实验动物,能增加血流量和营养性血流量,还有加强心肌收缩和增加耗氧量的作用。
2、对胆固醇代谢的影响:菊花水煎剂能抑制大鼠肝微粒体中的羟甲基戊二酰辅酶A还原酶(HMGR)的活力,激活胆固醇7-2-羟化酶,从而起到加速胆固醇代谢的作用。胡春等研究菊花提取物对大鼠血清胆固醇的升高有明显改善作用,对于正常的基础饲料组大鼠,菊花提取物能保持血清总胆固醇基本不变,而提高有保护作用的HDL浓度,降低有危害作用的LDL浓度,在高脂膳食情况下具有抑制血胆固醇和甘油三酯升高的作用。这对预防和治疗高血脂疾病无疑是有益的。
3、抗菌作用:杭菊在体外对大肠、宋内氏痢疾、变形菌、伤寒、副伤寒、绿脓及霍乱弧菌等7种革兰氏阴性肠内致病菌完全有抑制作用。并对金卜及β-溶血性链球菌有抗菌作用。对人型结核呈若干抑制作用。菊花水浸剂(1∶4)在试管内对堇色毛癣菌、同心性毛癣菌、许兰氏黄癣菌、奥杜盎氏小芽肥癣菌、铁锈色小芽胞癣菌、羊毛状小芽胞癣菌、腹股沟表皮癣菌、红色表皮癣菌、星形好卡氏菌等皮肤真菌均有不同程度的抑制作用。
4、抗病毒作用:山东省中医药研究所药理室对菊花八大主流商品进行了抗甲型流感病毒试验,结果表明各种菊花均有一定抗病毒作用,以亳菊、怀菊作用最好。国外研究发现菊花对单纯疱疹病毒(HSV-1)、脊髓灰质炎病毒和麻疹病毒具有不同程度的抑制作用,与空白组对照,空斑形成率减少50%。另外菊花还具有抗艾滋病作用,它能抑制ZV递转录酶和HLV复制的活性,从其中分离得到的金合欢素-7-0-B-D-0比喃半乳糖甙是抗HZV的新活性成分,且毒性相当低。
5、抗炎作用:山东省中医药研究所对菊花八大主流商品提取物进行小鼠抗炎作用比较,发现济菊、滁菊、杭菊、贡菊、川菊具有明显抗炎作用,而怀菊、亳菊、祁菊、黄菊有弱的抗炎作用或不明显。菊花提取物能影响小鼠毛细血管的通透性,增加毛细血管抵抗力,从而具有抗炎作用。
6、解热作用:菊花浸膏灌胃,对人工发热家兔有解热作用。
7、抗诱变作用:菊花对环磷酰胺诱发的小鼠骨髓PCE微核率有明显的抑制作用,平板掺入法试验也证实菊花对由2-氨基芴诱发的TA98或TA100菌株的回复突变呈现明显的抑制作用。
8、抗衰老作用:菊花能明显延长家蚕的寿命,可增强谷胱甘肽过氧化降低。菊花提取物可以提高小鼠心脑耐缺氧能力,延长生存时间。杭白菊还有清除O(2)自由基的能力。胡春等研究菊花提取物对生物膜的超氧阴离子自由基损伤的保护作用,发现菊花提取物可以进入细胞膜的甘油酯后而起保护作用,这一发现表明菊花有希望有新兴的功能性食品,特别是抗衰老食品中发挥作用。
9、抗肿瘤作用:从菊花中分离出来的蒲公英赛炮型3-羟基三萜类对由12-0-十四酰大戟二萜醇-13-酯(TPA)引起的小鼠皮肤肿瘤有较显著的抑制作用。
由上可见,采用本实施例的养生药酒,具有气味香浓,而且经实践表明,对调整五脏高血脂、肾功能、对失眠、内分泌及美容养颜具有良好的调理作用,并且毒性小,适合长期饮用。且纯天然不加任何色素。
在本实施例中,优选但不限于选用河南省焦作市内生长出厂的药物(俗称怀药)入药,实验证明,选用怀药可以具有更好的养生效果。
本实施例提供的养生保健酒的制作方法可以但不限于如下如图1所示,包括以下流程:
步骤101:将栀子30克放入5千克水中煮沸。
将栀子30克加入5千克水烧开、煮沸。
步骤102:在处于沸腾状态下的栀子水中混入1千克的白糖或蜂蜜500克原酒、以及药材。
在煮沸后,立即将其与原酒、以及药材混合。
药材的组分如下:当归:6克,陈皮:15克,红豆蔻:3克,白豆蔻:3克,官桂:3克,山奈:3克,高良姜:3克,独活:3克,锁阳:3克,薄荷:3克,莱菔子:3克,砂仁:3克,甘草:3克,檀香:3克,丁香:3克、山药:3克,菊花:3克;
优选但不限于选用河南省焦作市内生长出厂的药物(俗称怀药)入药,实验证明,选用怀药可以具有更好的养生效果。
步骤103:将步骤102得到的物质入罐,封口密封浸泡3天,即得。
以上对本发明实施例所提供的技术方案进行了详细介绍,本文中应用了具体个例对本发明实施例的原理以及实施方式进行了阐述,以上实施例的说明只适用于帮助理解本发明实施例的原理;同时,对于本领域的一般技术人员,依据本发明实施例,在具体实施方式以及应用范围上均会有改变之处,综上所述,本说明书内容不应理解为对本发明的限制。
Claims (4)
1.一种养生保健酒,其特征是,由以下组成:
白糖或蜂蜜500克,水:5千克,原酒:20斤1千克,当归:6克,陈皮:15克,红豆蔻:3克,白豆蔻:3克,官桂:3克,山奈:3克,高良姜:3克,独活:3克,锁阳:3克,薄荷:3克,莱菔子:3克,砂仁:3克,甘草:3克,檀香:3克,丁香:3克,栀子:30克,山药:3克,菊花:3克。
2.根据权利要求1所述的养生保健酒,其特征是,
所述当归、陈皮、红豆蔻、白豆蔻、官桂、山奈、高良姜、独活、锁阳、薄荷、莱菔子、砂仁、甘草、檀香、丁香、栀子选用河南省焦作市内生长的药物。
3.一种养生保健酒的制作方法,其特征是,包括:
将栀子30克放入5千克水中煮沸;
在处于沸腾状态下的栀子水中混入1千克的白糖或蜂蜜500克、以及原酒、以及以下药材:
当归:6克,陈皮:15克,红豆蔻:3克,白豆蔻:3克,官桂:3克,山奈:3克,高良姜:3克,独活:3克,锁阳:3克,薄荷:3克,莱菔子:3克,砂仁:3克,甘草:3克,檀香:3克,丁香:3克,山药:3克,菊花:3克;
封口密封浸泡3天。
4.根据权利要求1所述的养生保健酒的制作方法,其特征是,
所述当归、陈皮、红豆蔻、白豆蔻、官桂、山奈、高良姜、独活、锁阳、薄荷、莱菔子、砂仁、甘草、檀香、丁香、栀子、山药、菊花选用河南省焦作市内生长的药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110030173.4A CN102618420B (zh) | 2011-01-27 | 2011-01-27 | 一种养生保健酒以及制作方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110030173.4A CN102618420B (zh) | 2011-01-27 | 2011-01-27 | 一种养生保健酒以及制作方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102618420A true CN102618420A (zh) | 2012-08-01 |
CN102618420B CN102618420B (zh) | 2014-07-09 |
Family
ID=46558634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110030173.4A Active CN102618420B (zh) | 2011-01-27 | 2011-01-27 | 一种养生保健酒以及制作方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102618420B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104087468A (zh) * | 2014-06-19 | 2014-10-08 | 容家杨 | 一种用于低浓度无花果风味竹叶保健酒发酵的竹筒用具 |
CN109988693A (zh) * | 2019-04-29 | 2019-07-09 | 高晓霞 | 一种养生酒配方 |
CN113717820A (zh) * | 2021-09-03 | 2021-11-30 | 吴先球 | 一种调节人体机能的养生酒及其制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109825410A (zh) * | 2019-03-29 | 2019-05-31 | 河南友林酒业有限公司 | 一种保健酒及其制作工艺 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1192928A (zh) * | 1997-03-11 | 1998-09-16 | 凉城县鸿茅酒厂 | 药酒的生产方法 |
CN1799620A (zh) * | 2005-08-17 | 2006-07-12 | 王林祥 | 一种保健酒及其制备方法 |
CN101142996A (zh) * | 2007-09-28 | 2008-03-19 | 李怀海 | 一种肉食中药调味剂 |
-
2011
- 2011-01-27 CN CN201110030173.4A patent/CN102618420B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1192928A (zh) * | 1997-03-11 | 1998-09-16 | 凉城县鸿茅酒厂 | 药酒的生产方法 |
CN1799620A (zh) * | 2005-08-17 | 2006-07-12 | 王林祥 | 一种保健酒及其制备方法 |
CN101142996A (zh) * | 2007-09-28 | 2008-03-19 | 李怀海 | 一种肉食中药调味剂 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104087468A (zh) * | 2014-06-19 | 2014-10-08 | 容家杨 | 一种用于低浓度无花果风味竹叶保健酒发酵的竹筒用具 |
CN109988693A (zh) * | 2019-04-29 | 2019-07-09 | 高晓霞 | 一种养生酒配方 |
CN113717820A (zh) * | 2021-09-03 | 2021-11-30 | 吴先球 | 一种调节人体机能的养生酒及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102618420B (zh) | 2014-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Meireles et al. | A review of properties, nutritional and pharmaceutical applications of Moringa oleifera: integrative approach on conventional and traditional Asian medicine | |
CN101612360B (zh) | 治疗肝炎、肝硬化、肝癌的药物 | |
CN103585433B (zh) | 一种治疗口腔溃疡的中药组合物 | |
CN112868678A (zh) | 一种植物抗菌除螨剂及其制备方法和包含该植物抗菌除螨剂的日用品 | |
CN102618420B (zh) | 一种养生保健酒以及制作方法 | |
CN104351575A (zh) | 一种用于治疗猪痢疾的配合饲料及其制备方法 | |
CN1251732C (zh) | 一种治疗肺内感染的中药 | |
CN104436131A (zh) | 一种用于治疗猪痢疾的药物组合物及其制备方法 | |
CN104208393A (zh) | 一种用于防治鸡传染性支气管炎的中药组合物及其制备方法 | |
CN101238851A (zh) | 一种促肉鸡育肥增重的中药组合物及其制备方法 | |
CN102846713A (zh) | 治疗鸡传染性鼻炎的中草药口服液及其制备方法 | |
CN104472878A (zh) | 一种散养鸡饮水中草药添加剂 | |
CN103566312B (zh) | 一种治疗猪食欲不振的中药组合物 | |
CN108324920B (zh) | 一种治疗便秘的中药组合物及制备方法 | |
CN103099885A (zh) | 具有祛痤疮功能软胶囊及其制备方法 | |
CN105169102A (zh) | 清肺汤 | |
CN105639517A (zh) | 枇杷膏及其制备方法 | |
CN104399049A (zh) | 一种治疗寒性哮喘的中药混合物 | |
CN104971294A (zh) | 一种用于防治牛肺炎的中药组合物及口服剂 | |
CN103816399A (zh) | 一种用于治疗犬瘟热病的中药制剂 | |
CN104189637A (zh) | 治疗便溏的中药制剂 | |
CN104083748A (zh) | 一种治疗胃动力不足引起反酸的中药方剂 | |
CN103505675A (zh) | 一种治疗脂肪肝的中药组合物 | |
CN107233486A (zh) | 一种治疗咽炎的老盐柠檬组合物及其制备方法 | |
CN105343609A (zh) | 一种治疗口臭使口气清新的药物制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PP01 | Preservation of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20191014 Granted publication date: 20140709 |
|
DD01 | Delivery of document by public notice |
Addressee: Wang Dong Document name: Notice of preservation procedure |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Wang Dong Document name: Notice of commencement of preservation procedure |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Wang Dong Document name: payment instructions |
|
DD01 | Delivery of document by public notice |